iga glomerulonephritis

Summary

Summary: Chronic form of glomerulonephritis characterized by recurring hematuria with only slight proteinuria and by deposits of IMMUNOGLOBULIN A in the mesangial areas of the renal glomeruli. It usually occurs in young males.

Top Publications

  1. ncbi What is the difference between IgA nephropathy and Henoch-Schönlein purpura nephritis?
    J C Davin
    Department of Pediatrics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Kidney Int 59:823-34. 2001
  2. ncbi Efficacy of multidrug therapy combined with mizoribine in children with diffuse IgA nephropathy in comparison with multidrug therapy without mizoribine and with methylprednisolone pulse therapy
    Yukihiko Kawasaki
    Department of Pediatrics, Fukushima University School of Medicine, Fukushima, Japan
    Am J Nephrol 24:576-81. 2004
  3. ncbi Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors
    G D'Amico
    Department of Nephrology and Urology, San Carlo Borromeo Hospital, Milano, Italy
    Am J Kidney Dis 36:227-37. 2000
  4. ncbi Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy
    O Hotta
    Department of Nephrology, Sendai Shakaihoken Hospital, Sendai, Japan
    Am J Kidney Dis 38:736-43. 2001
  5. ncbi Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial
    Claudio Pozzi
    Department of Nephrology and Dialysis, A Manzoni Hospital, Lecco, Italy
    J Am Soc Nephrol 15:157-63. 2004
  6. ncbi Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy
    Francis W Ballardie
    Department of Nephrology, Royal Infirmary and University, Manchester, United Kingdom
    J Am Soc Nephrol 13:142-8. 2002
  7. ncbi IgA nephropathy
    Jonathan Barratt
    The John Walls Renal Unit, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK
    J Am Soc Nephrol 16:2088-97. 2005
  8. ncbi Predicting progression in IgA nephropathy
    L P Bartosik
    Metropolitan Toronto Glomerulonephritis Registry, University of Toronto, Toronto, Canada
    Am J Kidney Dis 38:728-35. 2001
  9. ncbi IgA nephropathy
    James V Donadio
    Division of Nephrology, Department of Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
    N Engl J Med 347:738-48. 2002
  10. ncbi Prognostic indicators of IgA nephropathy in the Chinese--clinical and pathological perspectives
    Philip Kam Tao Li
    Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, People s Republic of China
    Nephrol Dial Transplant 17:64-9. 2002

Detail Information

Publications232 found, 100 shown here

  1. ncbi What is the difference between IgA nephropathy and Henoch-Schönlein purpura nephritis?
    J C Davin
    Department of Pediatrics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Kidney Int 59:823-34. 2001
    ..Further studies are required to elucidate this possible mechanism as well as the role of hypersensitivity in HSPN...
  2. ncbi Efficacy of multidrug therapy combined with mizoribine in children with diffuse IgA nephropathy in comparison with multidrug therapy without mizoribine and with methylprednisolone pulse therapy
    Yukihiko Kawasaki
    Department of Pediatrics, Fukushima University School of Medicine, Fukushima, Japan
    Am J Nephrol 24:576-81. 2004
    ....
  3. ncbi Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors
    G D'Amico
    Department of Nephrology and Urology, San Carlo Borromeo Hospital, Milano, Italy
    Am J Kidney Dis 36:227-37. 2000
    ....
  4. ncbi Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy
    O Hotta
    Department of Nephrology, Sendai Shakaihoken Hospital, Sendai, Japan
    Am J Kidney Dis 38:736-43. 2001
    ..These findings indicate that interventions aimed at achieving clinical remission have provided encouraging results applicable to managing patients with IgA nephropathy...
  5. ncbi Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial
    Claudio Pozzi
    Department of Nephrology and Dialysis, A Manzoni Hospital, Lecco, Italy
    J Am Soc Nephrol 15:157-63. 2004
    ..The histologic picture and proteinuria during early and late follow-up improve the prediction of outcome, but considerable variability remains outside the model...
  6. ncbi Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy
    Francis W Ballardie
    Department of Nephrology, Royal Infirmary and University, Manchester, United Kingdom
    J Am Soc Nephrol 13:142-8. 2002
    ....
  7. ncbi IgA nephropathy
    Jonathan Barratt
    The John Walls Renal Unit, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK
    J Am Soc Nephrol 16:2088-97. 2005
  8. ncbi Predicting progression in IgA nephropathy
    L P Bartosik
    Metropolitan Toronto Glomerulonephritis Registry, University of Toronto, Toronto, Canada
    Am J Kidney Dis 38:728-35. 2001
    ..These results indicate that MAP and severity of proteinuria over time are the most important prognostic indicators of IgA nephropathy. The potential relevance of the algorithm in patient management is shown...
  9. ncbi IgA nephropathy
    James V Donadio
    Division of Nephrology, Department of Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
    N Engl J Med 347:738-48. 2002
  10. ncbi Prognostic indicators of IgA nephropathy in the Chinese--clinical and pathological perspectives
    Philip Kam Tao Li
    Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, People s Republic of China
    Nephrol Dial Transplant 17:64-9. 2002
    ..IgA nephropathy is the most common primary glomerulonephritis in the world. Up to 30% of patients can progress to end-stage renal disease (ESRD) in 10 years...
  11. ncbi Aberrant glycosylation in IgA nephropathy (IgAN)
    Rosanna Coppo
    Nephrology, Dialysis and Transplantation, Regina Margherita Hospital, Turin, Italy
    Kidney Int 65:1544-7. 2004
    ..Drugs can be targeted to the effects enhanced by aberrantly glycosylated IgA1 on mesangial cells. Recent data suggest that aberrant IgA1 glycosylation may modulate clinical expression and progression of IgAN...
  12. ncbi The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy
    Yuansheng Xie
    Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
    Kidney Int 63:1861-7. 2003
    ..Little information has been available until now about the clinical efficacy of tonsillectomy on long-term renal survival of patients with idiopathic immunoglobulin A nephropathy (IgAN)...
  13. ncbi Factors predicting progression of IgA nephropathies
    Rosanna Coppo
    Nephrology, Dialysis and Transplantation, Regina Margherita Hospital, Turin Italy
    J Nephrol 18:503-12. 2005
    ..Neither had prognostic value the finding of crescents involving up to 75% of glomeruli...
  14. pmc Enhanced intrarenal oxidative stress and angiotensinogen in IgA nephropathy patients
    Hiroyuki Kobori
    Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA 70112 2699, USA
    Biochem Biophys Res Commun 358:156-63. 2007
    ....
  15. ncbi Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy
    Li Xia Xu
    Renal Division and Institute of Nephrology, Peking University First Hospital, Beijing, People s Republic of China
    Kidney Int 68:167-72. 2005
    ..The aim of the current study is to investigate whether aberrantly glycosylated IgA1 was associated with pathologic phenotypes of IgAN...
  16. pmc Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci
    Luigi Bisceglia
    Medical Genetic Service, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
    Am J Hum Genet 79:1130-4. 2006
    ..Although we identified new candidate regions, replication studies are required to confirm the genetic contribution to familial IgAN...
  17. ncbi [A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy]
    XiangMei Chen
    Department of Nephrology General Hospital of Chinese PLA, Beijing 100853, China
    Zhonghua Yi Xue Za Zhi 82:796-801. 2002
    ..To investigate the effectiveness safety and tolerance of mycophenolate mofeil(MMF) in severe IgA nephropathy and evaluate the dosage adjustment and course for clinical treatment...
  18. ncbi Celiac disease and HLA DQ in patients with IgA nephropathy
    Pekka Collin
    Am J Gastroenterol 97:2572-6. 2002
    ..In this study, we sought to establish how common celiac disease is in patients with IgA nephropathy, and whether the possible association can be explained by similar HLA DQ status...
  19. ncbi A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study
    Kenji Wakai
    Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Nephrol Dial Transplant 21:2800-8. 2006
    ..Although there are several prognostic indicators, it remains difficult to predict the renal outcome in individual patients...
  20. ncbi The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group
    J V Donadio
    Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Am Soc Nephrol 10:1772-7. 1999
    ..Proteinuria was modestly reduced in both groups. It is concluded that early and prolonged treatment with fish oil slows renal progression for high-risk patients with IgA nephropathy...
  21. ncbi The long pentraxin PTX3 is synthesized in IgA glomerulonephritis and activates mesangial cells
    Benedetta Bussolati
    Cattedra di Nefrologia, Dipartimento di Medicina Interna, Università di Torino and Ospedale S Giovanni Battista, Torino, Italy
    J Immunol 170:1466-72. 2003
    ..an intense staining for PTX3 in the expanded mesangial areas of renal biopsies obtained from patients with IgA glomerulonephritis. The pattern of staining was on glomerular mesangial and endothelial cells...
  22. ncbi Mesangial IgA2 deposits and lectin pathway-mediated complement activation in IgA glomerulonephritis
    S Hisano
    Second Department of Pathology, Fukuoka University, School of Medicine, Fukuoka, Japan
    Am J Kidney Dis 38:1082-8. 2001
    ..We first report that mesangial deposits of IgA2 may activate the lectin pathway in patients with IgA GN...
  23. ncbi The predictive value of peritubular capillaries C3d deposition in IgA glomerulonephritis
    Mihaela Gherghiceanu
    Ultrastructural Pathology Laboratory, Babes National Institute of Pathology, Bucharest 050096, Romania
    J Cell Mol Med 9:143-52. 2005
    The IgA glomerulonephritis (IgAGN) is one of the most common primary glomerulonephritis and has a variable and difficult to predict evolution toward the end-stage nephrosclerosis...
  24. ncbi [Fabry nephropathy in a female with superposed IgA glomerulonephritis]
    A Pisani
    Universita Federico II di Napoli, Naples
    G Ital Nefrol 22:385-9. 2005
    ..However, female carriers can accumulate GSL in their renal cells despite the absence of clinically evident kidney disease...
  25. ncbi IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23
    A G Gharavi
    Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut, USA
    Nat Genet 26:354-7. 2000
    ..6 and 60% of kindreds linked. These findings for the first time indicate the existence of a locus with large effect on development of IgAN and identify the chromosomal location of this disease gene...
  26. ncbi Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial
    Manuel Praga
    Nephrology Department, Hospital 12 de Octubre, Madrid, Spain
    J Am Soc Nephrol 14:1578-83. 2003
    ..001 between groups). In conclusion, ACE inhibitors significantly improve renal survival in proteinuric IgAN with normal or moderately reduced renal function...
  27. ncbi Pathogenesis of IgA nephropathy
    Jonathan Barratt
    Department of Nephrology, Leicester General Hospital, Leicester, UK
    Semin Nephrol 24:197-217. 2004
    ..These new pathogenic insights have not yet led to new therapeutic opportunities...
  28. ncbi Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy
    T Shoji
    Department of Nephrology, Osaka Prefectural General Hospital, Japan
    Am J Kidney Dis 35:194-201. 2000
    ..EDA-FN did not change in either group. We conclude that early treatment with corticosteroids for adult diffuse proliferative IgA nephropathy is effective in reducing renal injury...
  29. ncbi Clinicopathologic correlation in IgA nephropathy
    David Philibert
    University Health Network, Toronto General Research Institute, Toronto, Canada
    Semin Nephrol 28:10-7. 2008
    ..These include the clinical scenarios of modest proteinuria, acute kidney injury, and the nephrotic syndrome...
  30. ncbi Glycosylation of circulating IgA in patients with IgA nephropathy modulates proliferation and apoptosis of mesangial cells
    A Amore
    Nephrology, Dialysis and Transplantation Department, Regina Margherita Hospital-Torino, Torino, Italy
    J Am Soc Nephrol 12:1862-71. 2001
    ..In conclusion, a significant modulation of several human MC functions exerted by serum IgA with increased exposure of GalNAc, Neu5Acalpha2,6GalNAc, and mannose residues isolated from IgAN patients is reported for the first time...
  31. ncbi Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy
    Ritsuko Katafuchi
    Kidney Unit, Fukuoka Red Cross Hospital, Fukuoka, Japan
    Am J Kidney Dis 41:972-83. 2003
    ..No accepted therapy has been established for progressive immunoglobulin A (IgA) nephropathy...
  32. ncbi Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials
    Joshua A Samuels
    UT Houston Health Science Center, Houston Texas, USA
    Nephrology (Carlton) 9:177-85. 2004
    ..43). Although the optimal management of patients with IgA nephropathy remains uncertain because of limitations with the existing published data, immunosuppressive agents are a promising strategy and should be investigated further...
  33. ncbi IgA nephropathy in children and adults: comparison of histologic features and clinical outcomes
    Mark Haas
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Nephrol Dial Transplant 23:2537-45. 2008
    ..Some of this variability may be related to differences in histologic severity of cohorts of patients diagnosed as children versus adults...
  34. ncbi Influence of cytokine gene polymorphisms on IgA nephropathy
    Christos Bantis
    Department of Nephrology, Heinrich Heine University Dusseldorf, Germany
    Ren Fail 30:135-40. 2008
    ..Conclusion. Our results suggest that TGF-beta1 gene Arg(25)-->Pro, TNFalpha gene G-308A, and IL-6 gene G-174C polymorphisms are not risk factors or markers of progression in Caucasian patients with IgA nephropathy...
  35. ncbi Interaction between ACE and ADD1 gene polymorphisms in the progression of IgA nephropathy in Japanese patients
    Ichiei Narita
    Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, 757, Asahimachi Dori, Niigata, 951 8510, Japan
    Hypertension 42:304-9. 2003
    ..65, P=0.2902). These findings suggest an interaction between ACE and ADD1 polymorphisms not only on blood pressure regulation but also on the progression of renal dysfunction in patients with IgAN...
  36. ncbi Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial
    Norishige Yoshikawa
    Department of Pediatrics, Wakayama Medical University, 811 1 Kimiidera, Wakayama 641 8509, Japan
    Clin J Am Soc Nephrol 1:511-7. 2006
    ..8 to 14.6 +/- 15.2% in the prednisolone group (P = 0.0003). The frequency of adverse effects was similar in the two groups. It is concluded that combination treatment may be better for severe IgAN than treatment with prednisolone alone...
  37. ncbi Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study
    Philip Kam Tao Li
    Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, Hong Kong
    Am J Kidney Dis 47:751-60. 2006
    ..We performed a double-blind, randomized, placebo-controlled, multicenter study on the ARB valsartan in the treatment of patients with immunoglobulin A (IgA) nephropathy...
  38. ncbi Polymorphism of angiotensin converting enzyme, angiotensinogen, and angiotensin II type 1 receptor genes and end-stage renal failure in IgA nephropathy: IGARAS--a study of 274 Men
    L Frimat
    Department of Nephrology, University Hospital, Nancy, France
    J Am Soc Nephrol 11:2062-7. 2000
    ..Compared with S(cr) and 24-P, genotypes DD, TT, and AA are unlikely to serve as clinically useful predictors of ESRF in IgAN...
  39. pmc Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy
    I C Moura
    Institut National de la Santé et de la Recherche Médicale INSERM U25, Necker Hospital, Paris 75743 Cédex 15, France
    J Exp Med 194:417-25. 2001
    ..The characterization of transferrin receptor as a novel IgA1 receptor on renal mesangial cells suggests its potential involvement in the pathogenesis of IgA nephropathy...
  40. ncbi Risk factors for IgA nephropathy: a case-control study with incident cases in Japan
    Kenji Wakai
    Department of Preventive Medicine Biostatistics and Medical Decision Making, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Nephron 90:16-23. 2002
    ..Our previous study with prevalent cases suggested that some genetic, immunological and lifestyle-related factors increased the risk of immunoglobulin A nephropathy (IgAN). To confirm this hypothesis, we conducted another case-control study...
  41. ncbi Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36
    Andrew D Paterson
    Hospital for Sick Children, University of Toronto, Ontario, Canada M5G 2N2
    J Am Soc Nephrol 18:2408-15. 2007
    ..Taken together, these data provide strong evidence for a novel disease susceptibility locus for familial IgAN...
  42. ncbi Polymorphisms of renin-angiotensin system genes in childhood IgA nephropathy
    K Maruyama
    Faculty of Health Science, Kobe University School of Medicine, Kobe, Hyogo, Japan
    Pediatr Nephrol 16:350-5. 2001
    ....
  43. ncbi Increased risk of end-stage renal disease in familial IgA nephropathy
    Francesco Paolo Schena
    Division of Nephrology, Dialysis and Transplantation, Department of Emergency and Organ Transplantation, University of Bari, Policlinico, Bari, Italy
    J Am Soc Nephrol 13:453-60. 2002
    ..This procedure might avoid late referral of subjects with persistent and underestimated urinary abnormalities and late diagnosis of the disease...
  44. ncbi Inflammatory markers and the progression of IgA glomerulonephritis
    Kati Kaartinen
    Kati Kaartinen, Kapteeninkatu 8 10 E 26, FIN 00140 Helsinki, Finland
    Nephrol Dial Transplant 23:1285-90. 2008
    b>IgA glomerulonephritis (IgAGN) composes a variable prognosis with 15-40% of the patients eventually progressing to end-stage renal failure...
  45. ncbi Role of proteinuria reduction in the progression of IgA nephropathy
    F Locatelli
    Department of Nephrology and Dialysis, Ospedale A Manzoni, Lecco, Italy
    Ren Fail 23:495-505. 2001
    ..Proteinuria has been shown to play a causal role in the progression towards ESRD of IgA nephropathy (IgAN). We demonstrated that steroids are effective in reducing proteinuria and preserving renal function...
  46. ncbi ACE gene polymorphism and IgA nephropathy: an ethnically homogeneous study and a meta-analysis
    F P Schena
    Division of Nephrology, Department of Emergency and Organ Transplantation, University of Bari, Policlinic, Bari, Italy
    Kidney Int 60:732-40. 2001
    ..Conflicting results have implicated the angiotensin-converting enzyme (ACE) D allele in the progression of renal damage in patients with IgA nephropathy (IgAN). Most of these findings have been obtained by heterogeneous studies...
  47. ncbi Angiotensin I-converting enzyme genotype significantly affects progression of IgA glomerulonephritis in an italian population
    P Stratta
    Epidemiology Unit of Cancer, Service of Transplant Immunology of the University of Torino, Torino, Italy
    Am J Kidney Dis 33:1071-9. 1999
    ..However, on the basis of current knowledge, we cannot exclude that I/D polymorphism may simply serve as a prognostic marker, eventually linked with other discrete loci involved in the progression of renal damage...
  48. ncbi Efficacy of prednisolone and mizoribine therapy for diffuse IgA nephropathy
    Yukihiko Kawasaki
    Department of Pediatrics, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan
    Am J Nephrol 24:147-53. 2004
    ..There have been only a few studies concerning oral prednisolone and mizoribine therapy for diffuse IgA nephritis (IgAN). We evaluated the efficacy of prednisolone and mizoribine therapy for diffuse IgAN...
  49. ncbi Aberrantly glycosylated IgA1 in glomerular immune deposits of IgA nephropathy
    Konstantinos Giannakakis
    Department of Experimental Medicine, La Sapienza University, Rome, Italy
    J Am Soc Nephrol 18:3139-46. 2007
  50. pmc Binding capacity and pathophysiological effects of IgA1 from patients with IgA nephropathy on human glomerular mesangial cells
    Y Wang
    Renal Division and Institute of Nephrology, Peking University First Hospital, Beijing, China
    Clin Exp Immunol 136:168-75. 2004
    ..This suggests that direct interaction between IgA1 and HMC and subsequential pathophysiological responses may play an important role in the pathogenesis for IgAN...
  51. ncbi Minimal change variants with mesangial IgA deposits
    H Matsukura
    Clin Nephrol 68:337-8. 2007
  52. ncbi Treatment of primary IgA nephropathy
    Efstathios Alexopoulos
    Hippokration General Hospital, Thessaloniki, Greece
    Kidney Int 65:341-55. 2004
  53. ncbi Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study
    Norishige Yoshikawa
    Department of Pediatrics, Wakayama Medical University, 811 1 Kimiidera, Wakayama, Japan
    Pediatr Nephrol 23:757-63. 2008
    ..No patients required a change of treatment. In conclusion, the efficacy and safety of the mizoribine combination seems to be acceptable for treating children with severe IgA-N...
  54. ncbi Pathogenesis of IgA nephropathy
    Jun Wada
    Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
    Semin Nephrol 23:556-63. 2003
    ....
  55. ncbi Primary glomerulonephritis: an update on renal survival and determinants of progression
    O Moranne
    INSERM Unit 780, 16, avenue Paul Vaillant Couturier, 94807 Villejuif Cedex, France
    QJM 101:215-24. 2008
    ..Few epidemiological studies have investigated the long-term outcome of primary glomerulonephritis (GN) and its determinants in the decade since angiotensin-converting enzyme inhibitors entered widespread use...
  56. ncbi A family-based association study of megsin A23167G polymorphism with susceptibility and progression of IgA nephropathy in a Chinese population
    Y F Xia
    Department of Nephrology, First Affiliated Hospital, Sun Yat Sen University, Guangzhou, China
    Clin Nephrol 65:153-9. 2006
    ..To investigate the association of megsin A23167G polymorphism with susceptibility and progression of IgA nephropathy in Chinese population...
  57. ncbi Vitamin E therapy in IgA nephropathy: a double-blind, placebo-controlled study
    James C M Chan
    Virginia Commonwealth University, Richmond, Virginia, USA
    Pediatr Nephrol 18:1015-9. 2003
    ....
  58. ncbi No evidence for a role of cosmc-chaperone mutations in European IgA nephropathy patients
    Friederike Malycha
    Department of Human Genetics, Division of Nephrology and Immunology, Aachen, Germany
    Nephrol Dial Transplant 24:321-4. 2009
    ..Mosaic mutations of cosmc have been shown to result in autoimmune disease. We hypothesized that cosmc mutations might contribute to the altered IgA1 galactosylation in IgAN patients...
  59. ncbi New insights into the pathogenesis of IgA nephropathy. Pathogenesis of IgA nephropathy
    Alice C Smith
    Department of Nephrology, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK
    Springer Semin Immunopathol 24:477-93. 2003
  60. ncbi Inherited forms of IgA nephropathy
    Francesco Scolari
    Division of Nephrology, Spedali Civili, Ple Ospedale Civili 1, 25125 Brescia, Italy
    J Nephrol 16:317-20. 2003
    ..Future study will be focused on the identification of the gene underlying IGAN-1. This will enable us to understand the molecular pathogenetic basis of IgAN...
  61. ncbi Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent
    Ronald J Hogg
    St Joseph s Hospital and Medical Center, Phoenix, AZ 85013, USA
    Clin J Am Soc Nephrol 1:1167-72. 2006
    ..38, P < 0.001). It is concluded from these data that the effect of Omacor on proteinuria in patients with IgAN is dosage dependent and is associated with a dosage-dependent effect of Omacor on plasma phospholipid EPA and DHA levels...
  62. ncbi Transforming growth factor-beta1 gene polymorphism modifies the histological and clinical manifestations in Japanese patients with IgA nephropathy
    F Sato
    Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
    Tissue Antigens 64:35-42. 2004
    ..These results suggest that TGF-beta1 gene polymorphisms are specifically associated with heavy proteinuria and mesangial cell proliferation in Japanese patients with IgAN, although they do not confer susceptibility to this disease...
  63. ncbi Association of functional haem oxygenase-1 gene promoter polymorphism with polycystic kidney disease and IgA nephropathy
    Aisling E Courtney
    Nephrology Research Group, Queen s University Belfast, Belfast, UK
    Nephrol Dial Transplant 23:608-11. 2008
    ..We report the first assessment of the role of this HO-1 gene promoter polymorphism in chronic kidney disease due to autosomal dominant polycystic kidney disease (ADPKD) and IgA nephropathy (IgAN)...
  64. ncbi Peripheral B lymphocyte beta1,3-galactosyltransferase and chaperone expression in immunoglobulin A nephropathy
    W Qin
    Division of Nephrology, Department of Internal Medicine, Sichuan University West China Hospital, Chengdu, Sichuan, China
    J Intern Med 258:467-77. 2005
    ..The current study was carried out to elucidate the expression level of beta1,3GT (C1GALT1) and its chaperone (Cosmc) in IgAN, and their relationships with clinical features as well as IgA glycosylation level...
  65. ncbi Clinicopathological features and the prognosis of IgA nephropathy in Japanese children on long-term observation
    R Nozawa
    Department of Pediatrics, Fukushima Medical University School of Medicine, Fukushima, Japan
    Clin Nephrol 64:171-9. 2005
    ..Clinicopathological features were investigated to clarify the ultimate prognosis and prognostic indicators for patients with IgA nephropathy in Japanese children...
  66. ncbi Mesangial IgA deposition in minimal change nephrotic syndrome: coincidence of different entities or variant of minimal change disease?
    T H Westhoff
    Charite Campus Benjamin Franklin, Medical Clinic IV, Nephrology, Hindenburgdamm 30, Berlin, Germany
    Clin Nephrol 65:203-7. 2006
    ..We describe 2 cases of MCA with analogue histological findings but relevant differences in clinical presentation, and we discuss the clinical implications of mesangial IgA deposition in minimal change nephrotic syndrome...
  67. ncbi IgA nephropathy: the presence of familial disease does not confer an increased risk for progression
    Claudia Izzi
    Divisione di Nefrologia, Università e Spedali Civili, Brescia, Italy
    Am J Kidney Dis 47:761-9. 2006
    ..Familial and sporadic cases are recognized, and a locus associated with the familial form of the disease was mapped to chromosome 6. Recent data suggest the familial IgA nephropathy form may have a poorer outcome than the sporadic form...
  68. ncbi Insulin resistance and the progression of IgA glomerulonephritis
    Kati Kaartinen
    Department of Internal Medicine, Tampere University Hospital, Tampere, Finland
    Nephrol Dial Transplant 22:778-83. 2007
    b>IgA glomerulonephritis (IgAGN) has a highly variable prognosis with 15-40% of patients progressing to end-stage renal disease. Hypertension, proteinuria and renal insufficiency are risk factors associated with poor prognosis...
  69. ncbi Association of C-509T and T869C polymorphisms of transforming growth factor-beta1 gene with susceptibility to and progression of IgA nephropathy
    C S Lim
    Department of Internal Medicine, Seoul National University Boramae Hospital, Seoul, Korea
    Clin Nephrol 63:61-7. 2005
    ..The transcriptional activity of the gene for TGF-beta1 and the plasma levels of TGF-beta1 protein are associated with C-509T polymorphism at the promoter region, and with T869C (Leu 10Pro) polymorphism at codon 10, of the TGF-beta1 gene...
  70. ncbi Tissue-specific expression of renin-angiotensin system components in IgA nephropathy
    Chie Miyake-Ogawa
    Division of Nephrology, Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan
    Am J Nephrol 25:1-12. 2005
    ....
  71. ncbi Association between transforming growth factor beta1 gene polymorphisms and IgA nephropathy
    Sonia Carturan
    Department of Medicine and Experimental Oncology, University of Turin, Turin, Italy
    J Nephrol 17:786-93. 2004
    ..We investigated whether G-800A, C-509T and Leu10-->Pro polymorphisms in the TGF-beta1 gene could be involved in the development and progression of immunoglobulin A nephropathy (IgAN)...
  72. ncbi Variants of C1GALT1 gene are associated with the genetic susceptibility to IgA nephropathy
    G S Li
    Renal Division, Department of Internal Medicine, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China
    Kidney Int 71:448-53. 2007
    ..0298, P=1.258 x 10(-5), OR=3.03) were significantly higher in patients than in controls. The present study suggested that the polymorphisms of C1GALT1 gene were associated with the genetic susceptibility to IgAN in Chinese population...
  73. ncbi Early prediction of IgA nephropathy progression: proteinuria and AOPP are strong prognostic markers
    Beatrice Descamps-Latscha
    INSERM U507 and Department of Nephrology, Necker Hospital, Paris, France
    Kidney Int 66:1606-12. 2004
    ....
  74. ncbi T-cell homing receptor expression in IgA nephropathy
    Arvind Batra
    Department of Infection, Immunity and Inflammation, University of Leicester, and John Walls Renal Unit, Leicester General Hospital, Leicester LE5 4PW, UK
    Nephrol Dial Transplant 22:2540-8. 2007
    ..We investigated the HR expression of T-cell subsets in IgAN, healthy adults and membranous nephropathy (MN)...
  75. ncbi Angiotensin antagonists and fish oil for treating IgA nephropathy
    R Coppo
    Pediatric Nephrology School, Nephrology, Dialysis and Transplantation Department, Regina Margherita University Hospital, Turin, Italy
    Contrib Nephrol 157:27-36. 2007
    ..In conclusion, ACE-I and ARB have a definite role in treating IgAN, particularly the hypertensive and proteinuric forms. These patients should be treated to target BP to <130/70 mm Hg and proteinuria <0.5 g/day...
  76. ncbi FB21, a monoclonal antibody that reacts with a sialic-acid-dependent carbohydrate epitope, is a marker for glomerular endothelial cell injury
    Yukihiko Kawasaki
    Department of Pediatrics Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan
    Am J Kidney Dis 44:239-49. 2004
    ..We evaluated FB21 staining in fetal kidneys and kidneys of children and adults with normal kidneys and glomerulonephritis and investigated whether FB21 can be used as a marker for endothelial cell injury...
  77. ncbi The genetics of IgA nephropathy
    Isabel Beerman
    Department of Genetics, Yale University, New Haven, CT, USA
    Nat Clin Pract Nephrol 3:325-38. 2007
    ..We discuss recent developments in analytic tools that should enable genetic studies of sporadic forms of disease by the genome-wide association approach...
  78. ncbi [Steroid-responsive nephrotic syndrome in IgA nephropathy]
    R M García Camín
    Servicio de Nefrologia, Fundacion Puigvert, Barcelona, Espana
    Nefrologia 24:68-71. 2004
    ..6 g/d and C. creat. 59 ml/min...
  79. ncbi Association of IgA nephropathy with T-cell receptor constant alpha chain gene polymorphism
    P K Li
    Department of Medicine, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin
    Am J Kidney Dis 30:260-4. 1997
    ..It is concluded that the TCR C-alpha gene is associated with IgAN but not with the prognosis of the disease...
  80. ncbi Association of the uteroglobin gene polymorphism with IgA nephropathy
    Akira Matsunaga
    Department of Pediatrics, Yamagata University School of Medicine, Yamagata, Japan
    Am J Kidney Dis 39:36-41. 2002
    ....
  81. ncbi Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy
    D Russo
    Department of Nephrology, School of Medicine, University Federico II, Italy
    Am J Kidney Dis 38:18-25. 2001
    ....
  82. ncbi Evidence-based assessment of treatment options for children with IgA nephropathies
    R J Wyatt
    Le Bonheur Children's Medical Center and The Center for Health Policy, University of Tennessee Health Science Center, Memphis 38103, USA
    Pediatr Nephrol 16:156-67. 2001
    ..Well designed randomized controlled trials in children with the IgA nephropathies need to be undertaken...
  83. ncbi A(-20)C polymorphism of the angiotensinogen gene and progression of IgA nephropathy
    Shin Goto
    Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Asahimachi 1 757, Niigata 951 8510, Japan
    Kidney Int 62:980-5. 2002
    ..Recent studies showed that nucleotide substitution in the 5' upstream core promoter region of AGT affects the basal transcription rate of the gene...
  84. ncbi Evidence for genetic factors in the development and progression of IgA nephropathy
    S I Hsu
    Departments of Medicine and Pediatrics, Faculty of Medicine, National University of Singapore
    Kidney Int 57:1818-35. 2000
    ..The task of elucidating the molecular basis of IgAN is made especially challenging by the fact that both environmental and genetic components likely contribute to the development and progression of IgAN...
  85. ncbi Single-nucleotide polymorphisms in the class II region of the major histocompatibility complex in Japanese patients with immunoglobulin A nephropathy
    Fumihiro Akiyama
    Human Genome Center, The Institute of Medical Science, University of Tokyo, Japan
    J Hum Genet 47:532-8. 2002
    ..000001, odds ratio = 1.91 [95% confidence interval 1.46-2.49]); SNPs in other LD blocks were not. Our data imply that some haplotype of the HLA- DRA locus has an important role in the development of IgAN in Japanese patients...
  86. ncbi Controversies concerning the importance of genetic polymorphism in IgA nephropathy
    Luc Frimat
    Nephrol Dial Transplant 17:542-5. 2002
  87. ncbi Mizoribine treatment for childhood IgA nephropathy
    Rieko Nagaoka
    Department of Pediatrics, Juntendo University School of Medicine, Tokyo, Japan
    Pediatr Int 44:217-23. 2002
    ..Our preliminary study demonstrated that mizoribine could reduce the amount of proteinuria in children with IgAN. The present study was conducted to confirm this finding...
  88. ncbi Familial clustering of IgA nephropathy: further evidence in an Italian population
    F Scolari
    Division of Nephrology, Spedali Civili, Brescia, Italy
    Am J Kidney Dis 33:857-65. 1999
    ..In addition, this subgroup of patients with IgA nephropathy offers an ideal opportunity to elucidate the molecular genetics of this disease...
  89. pmc Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies
    M Tomana
    Department of Medicine, Division of Clinical Immunology and Rheumatology, The University of Alabama Birmingham, Birmingham, Alabama 35294 2041, USA
    J Clin Invest 104:73-81. 1999
    ..Our results suggest that the deficiency of Gal in the hinge region of IgA1 molecules results in the generation of antigenic determinants containing GalNAc residues that are recognized by naturally occurring IgG and IgA1 antibodies...
  90. ncbi New insights in the pathogenesis of IgA nephropathy
    R C Monteiro
    INSERM U699, Bichat Medical School, 16 Rue Henri Huchard BP416, 75870 Paris, France
    Nefrologia 25:82-6. 2005
    ..The elucidation of IgA-receptor interactions may open new avenues for drug design and treatment of IgAN...
  91. ncbi Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease
    Anja Roos
    Department of Clinical Chemistry, Leiden University Medical Center, The Netherlands, and Fonazione D Amico per la Ricerca sulle Malattie Renali, Associazione Nuova Nefrologia, San Carlo Borromeo Hospital, Milano, Italy
    J Am Soc Nephrol 17:1724-34. 2006
    ..Together, these findings strongly point to a role for the lectin pathway of complement in glomerular complement activation in IgAN and suggest a contribution for both MBL and L-ficolin in the progression of the disease...
  92. ncbi Specific tissue distribution of megsin, a novel serpin, in the glomerulus and its up-regulation in IgA nephropathy
    R Inagi
    Molecular and Cellular Nephrology, Tokai University School of Medicine, Kanagawa, Japan
    Biochem Biophys Res Commun 286:1098-106. 2001
    ....
  93. ncbi Development of immune-complex glomerulonephritis in athymic mice: T cells are not required for the genesis of glomerular injury
    Nayer Bagheri
    Department of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA
    Lab Invest 85:354-63. 2005
    ..001). These results indicate that chronic injection of DEAE-DEX into athymic mice generates the same clinical and histologic features of GN as in euthymic mice, suggesting that T cells are not necessary to promote GN in this model...
  94. ncbi Primary IgA nephropathy with low histologic grade and disease progression: is there a "point of no return"?
    Fernand Mac Moune Lai
    Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China
    Am J Kidney Dis 39:401-6. 2002
    ....
  95. ncbi Immunohistochemical detection of immunoglobulins and complements in formaldehyde-fixed and paraffin-embedded renal biopsy tissues; an adjunct for diagnosis of glomerulonephritis
    Akm Rownak Hossain Chowdhury
    Department of Histopathology, Shaheed Ziaur Rahman Medical College, Bogra, Bangladesh
    Nephrology (Carlton) 10:298-304. 2005
    ....
  96. ncbi CD44 expression in IgA nephropathy
    Sandrine Florquin
    Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Am J Kidney Dis 39:407-14. 2002
    ..CD44 may have a pivotal role in the cascade of renal inflammation and fibrosis...
  97. ncbi Coexistence of IgA nephropathy and undifferentiated spondyloarthropathy in a female patient
    Masayuki Matsuda
    Third Department of Medicine, Shinshu University School of Medicine, 3 1 1 Asahi, Matsumoto 390 8621, Japan
    Clin Rheumatol 25:415-8. 2006
    ..Possible association of this disorder should be carefully checked in patients with IgA nephropathy irrespective of clinical symptoms suggesting the arthropathy, particularly in women...
  98. ncbi [Clinical analysis of proteinuria and glomerular lesions in Henoch-Schönlein purpura nephritis of adults]
    Dong yan Liu
    Department of Nephrology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao 27:237-40. 2005
    ..To analyze the characteristics of proteinuria and glomerular lesions in Henoch-Schönlein purpura nephritis (HSPN) of adults...
  99. ncbi Regression of IgA nephropathy: a repeat biopsy study
    Osamu Hotta
    Department of Nephrology, Sendai Shakaihoken Hospital, Sendai, Japan
    Am J Kidney Dis 39:493-502. 2002
    ..A histological cure may be obtainable in a considerable proportion of patients, especially if treatment is initiated at a relatively early stage...
  100. ncbi Pathology of glomerular deposition diseases
    Kensuke Joh
    Division of Immunopathology, Clinical Research Center, Chiba East National Hospital, Chuo Ku, Chiba, Japan
    Pathol Int 57:551-65. 2007
    ....
  101. ncbi [IGA-nephropathy with nephrotic syndrome as an extrapulmonary manifestation of sarcoidosis]
    B M Kornev
    Klin Med (Mosk) 83:83-6. 2005

Research Grants14

  1. PREVENTION OF GRAFT FAILURE TO DIETARY N-3 FATTY ACIDS
    James Tumlin; Fiscal Year: 2002
    ..Secondary outcomes to be compared are molecular markers for thrombosis, inflammation, and vascular risk factors. ..
  2. DIETARY LIPIDS AND EXPERIMENTAL IGA NEPHROPATHY
    James Pestka; Fiscal Year: 2009
    ..abstract_text> ..
  3. PERIODONTAL DISEASE:ROLE OF ABERRANT Ig GLYCOSYLATION
    Jiri Mestecky; Fiscal Year: 2006
    ..Results of these studies will generate information concerning previously unexplored inflammatory pathways that participate in the development of PD. ..
  4. Intrarenal Augmentation of Angiotensinogen by Ang II
    Hiroyuki Kobori; Fiscal Year: 2010
    ..abstract_text> ..
  5. Cordyceps Sinensis Evaluation in IgA Nephropathy Model
    Abdalla Rifai; Fiscal Year: 2005
    ..These studies will generate novel insights into molecular mechanisms underlying pathogenesis of IgA nephropathy and predict outcomes from safe traditional alternative medicine for prevention of renal failure. ..
  6. ENDOTOXIN AND SUSCEPTIBILITY TO TRICHOTHECENE MYCOTOXINS
    James Pestka; Fiscal Year: 2002
    ..Over the long term, this research will provide insight into adverse immunologic consequences that may occur in LPS-exposed individuals who are exposed to environmental toxicants." ..
  7. Familial IgA Nephropathy: Genetic and Metabolic Studies
    Jiri Mestecky; Fiscal Year: 2006
    ..abstract_text> ..
  8. Signaling Pathways in Pathogenesis of Renal Fibrosis
    JOSEPH GRANDE; Fiscal Year: 2004
    ..If successful, these interventions may retard progression of tissue injury to end-stage disease. ..
  9. CELLULAR SIGNALING IN RENAL PATHOPHYSIOLOGY
    JOSEPH GRANDE; Fiscal Year: 2008
    ..abstract_text> ..
  10. Urinary Podocyte Excretion Using FACS Methodology
    Kevin Lemley; Fiscal Year: 2003
    ..e. is podocyturia an earlier biomarker of incipient nephropathy? and 2) do the responses of albuminuria and podocyturia to treatment with angiotensin-converting enzyme inhibitors differ? ..
  11. Genetic Determinants of Vesicoureteral Reflux
    Ali Gharavi; Fiscal Year: 2007
    ..Identification of genes underlying VUR will provide novel approaches to detect patients at risk and may enable the development of novel therapeutic approaches for this disorder [unreadable] [unreadable]..
  12. Genetic studies - renal failure in HIV-1 transgenic mice
    Ali Gharavi; Fiscal Year: 2004
    ..These studies will also be conducted in chromosome 8 congenic mice trapping loci flanking the transgene. ..
  13. Genetic Determinants of Human Non - Syndromic Urinary Tract Malformations
    Ali Gharavi; Fiscal Year: 2008
    ..Identification of genes underlying this trait will provide novel approaches to detect patients at risk and may enable the development of novel therapeutic approaches for this disorder [unreadable] [unreadable] [unreadable]..
  14. ICAM1 gene inactivation protects against ischemic injury
    Robert Montgomery; Fiscal Year: 2006
    ..This work has important implications for the selective inactivation of gene function in allografts through ex vivo gene transfer. ..